About LifeMine Therapeutics
LifeMine Therapeutics is a company based in Cambridge (United States) founded in 2016 by Gregory Verdine and Weiqing Zhou. LifeMine Therapeutics has raised $300.07 million across 5 funding rounds from investors including Fidelity Investments, Arch Venture Partners and GSK. The company has 85 employees as of December 31, 2020. LifeMine Therapeutics offers products and services including LIFE-001 and Top-Down Drug Discovery Engine. LifeMine Therapeutics operates in a competitive market with competitors including Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
- Headquarter Cambridge, United States
- Employees 85 as on 31 Dec, 2020
- Founders Gregory Verdine, Weiqing Zhou
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lifemine Therapeutics
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$300.07 M (USD)
in 5 rounds
-
Latest Funding Round
$175 M (USD), Series C
Mar 23, 2022
-
Investors
Fidelity Investments
& 13 more
-
Employee Count
85
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LifeMine Therapeutics
LifeMine Therapeutics offers a comprehensive portfolio of products and services, including LIFE-001 and Top-Down Drug Discovery Engine.
Precision-engineered inhibitor for treating immune-mediated diseases and transplant rejection.
Data-driven system for uncovering novel precision medicines from fungal sources.
People of LifeMine Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of LifeMine Therapeutics
LifeMine Therapeutics has successfully raised a total of $300.07M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $175 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LifeMine Therapeutics
LifeMine Therapeutics has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Arch Venture Partners and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for LifeMine Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LifeMine Therapeutics
Investment portfolio details for LifeMine Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LifeMine Therapeutics
Detailed financials for LifeMine Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lifemine Therapeutics Comparisons
Peer comparison for LifeMine Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LifeMine Therapeutics
LifeMine Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
Detailed competitors of LifeMine Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lifemine Therapeutics
Complete news archive for LifeMine Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LifeMine Therapeutics
LifeMine Therapeutics was founded in 2016.
LifeMine Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Gregory Verdine is the current CEO of LifeMine Therapeutics. They have also founded this company.
LifeMine Therapeutics is a funded company, having raised a total of $300.07M across 5 funding rounds to date.
As of Dec 31, 2020, the latest employee count at LifeMine Therapeutics is 85.
LifeMine Therapeutics was founded in 2016 in Cambridge, Massachusetts, United States. Operations focus on the biotech sector, where fungal genomes are mined and recombinant overexpression is applied to identify new molecules. These compounds are targeted for treating difficult human diseases through unconventional biological pathways. The approach involves extensive exploration of the fungal biosphere to uncover potential therapeutics.
LifeMine Therapeutics's top competitors include Syngenta, Sutro Biopharma and Avidity Biosciences.
LifeMine Therapeutics offers LIFE-001 and Top-Down Drug Discovery Engine.
LifeMine Therapeutics has 14 investors. Key investors include Fidelity Investments, Arch Venture Partners, GSK, Invus, and 3W Partners.